NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In type 2 diabetics, progression from chronic kidney disease to end stage renal disease may
be slowed down by therapeutic interventions as angiotensin converting enzyme inhibitors use,
control of high blood pressure and proteinuria, control of hyperglycaemia, protein intake
restriction, smoking cessation.
Correcting anaemia in these patients may prevent impairment of renal function. International
guidelines indicate that haemoglobin level has to be of 110 g/L in these patients. We conduct
an interventional randomized trial to evaluate the potential benefit of an haemoglobin level
of 130 g/L in patients with type 2 diabetes and with a chronic kidney disease defined by a
Cockcroft's creatinine clearance of 25 - 60 ml/min.